ARA-290
Concentration calculator
Research summary
ARA-290 (cibinetide) is a synthetic peptide derived from a surface region of erythropoietin, engineered to activate a tissue-protection and nerve-repair pathway without triggering erythropoietin's blood-cell-producing effects.
In a randomized, double-blind Phase 2 trial in 64 patients with sarcoidosis-associated small-fiber neuropathy, a tested dose produced a statistically significant increase in corneal nerve fiber density versus placebo, along with reductions in pain intensity in patients with moderate-to-severe baseline pain. Despite meeting these endpoints, no Phase 3 trial was ever run, and development stopped after the sponsoring company ceased operations.
Sources: Expert Opinion on Investigational Drugs, 2014 (Dahan et al.); ClinicalTrials.gov NCT02039687. Findings from published research —not a claim about this product, and not evidence of safety or effectiveness for human use.
Decoding the Benefits
- Significantly increased nerve fiber density in a 64-patient randomized trial — a rare objective finding in nerve-pain studies.
- Patients with the worst baseline pain saw the clearest reductions.
